NCT03252171

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Detailed description

Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at GD2 antigen. After CAR-T cell infusion, At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study, the investigators will evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.

Conditions

• GD2 Positive Glioma
• CAR-T Cell Immunotherapy

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T cell immunotherapy	This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.

Timeline

• Start date: 2015-10-15
• Primary completion: 2016-08-15
• Completion: 2016-08-15
• First posted: 2017-08-17
• Last updated: 2020-07-16

Locations

1 site across 1 country: China